Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
19 participants
OBSERVATIONAL
2018-04-02
2019-02-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Both medical and surgical patients will be included. Any type of infections can be included (pulmonary, abdominal, urinary tract, etc.) Antibiotics regimen includes one-hour infusion of meropenem (1.0 gram) intravenously every 8 hours.
Blood samples (2 mL) will be collected at the 15, 30, 45, 60, 75, 90, 120, 180, 240, and 480 minutes after each dose of meropenem for 3 consecutive days. The standard arterial canula will be used to obtain samples.
30 minutes after each sample collection, blood will be centrifuged for 10 minutes at 3,000 rpms. Subsequently, supernatant will be collected and frozen.
Serum meropenem concentration will be measured by high-performance liquid chromatography.
Each patient's hemodynamic parameters will be recorded with the use of transpulmonary thermodilution technique (PICCO). Other therapies, i.e. ventilatory support, sedation, an antifungal agent will be given as required.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Meropenem
Patients who require meropenem and CRRT during ICU (intensive care unit) stay
Meropenem
1.0 gram of meropenem given intravenously every 8 hours
CRRT
Continuous renal replacement therapy for three days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Meropenem
1.0 gram of meropenem given intravenously every 8 hours
CRRT
Continuous renal replacement therapy for three days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age 18-80 years
* an eligible consent obtained from the patient or his/her attendant
Exclusion Criteria
* lack of consent to participate in the study
* age of patients below 18 or above 80 years
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Warmia and Mazury in Olsztyn
OTHER
Medical University of Lublin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Michał Borys
M.D., Ph.D.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oddział Kliniczny Anestezjologii i Intensywnej Terapii, Wojewódzki Szpital Specjalistyczny w Olsztynie
Olsztyn, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
90/2009/IV
Identifier Type: -
Identifier Source: org_study_id